113 related articles for article (PubMed ID: 11861218)
21. Higher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection.
Kim HJ; Song ES; Hwang TS
Eur J Obstet Gynecol Reprod Biol; 2001 Oct; 98(2):213-8. PubMed ID: 11574134
[TBL] [Abstract][Full Text] [Related]
22. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
23. Localization of p53 protein and human papillomavirus in anogenital squamous lesions: immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia.
Walts AE; Koeffler HP; Said JW
Hum Pathol; 1993 Nov; 24(11):1238-42. PubMed ID: 8244324
[TBL] [Abstract][Full Text] [Related]
24. The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis.
Breitburd F; Salmon J; Orth G
Clin Dermatol; 1997; 15(2):237-47. PubMed ID: 9167908
[No Abstract] [Full Text] [Related]
25. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of the human homologue of drosophila discs large oncosuppressor in histologic samples from human papillomavirus-associated lesions as a marker for progression to malignancy.
Cavatorta AL; Fumero G; Chouhy D; Aguirre R; Nocito AL; Giri AA; Banks L; Gardiol D
Int J Cancer; 2004 Sep; 111(3):373-80. PubMed ID: 15221964
[TBL] [Abstract][Full Text] [Related]
27. Increased angiogenesis in the uterine cervix associated with human papillomavirus infection.
Nair P; Gangadevi T; Jayaprakash PG; Nair MB; Nair MK; Pillai MR
Pathol Res Pract; 1999; 195(3):163-9. PubMed ID: 10220796
[TBL] [Abstract][Full Text] [Related]
28. [Ha-ras and p53 gene mutations scanned by PCR-SSCP in premalignant and malignant lesions of the uterine cervix associated with human papillomavirus].
Alonio LV; Dalbert D; Picconi MA; Cervantes Vazquez G; García Carrancá A; Distefano AL; Mural J; Bartt O; Bazan G; Teyssie AR
Medicina (B Aires); 2000; 60(6):895-901. PubMed ID: 11436698
[TBL] [Abstract][Full Text] [Related]
29. The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India.
Munirajan AK; Kannan K; Bhuvarahamurthy V; Ishida I; Fujinaga K; Tsuchida N; Shanmugam G
Gynecol Oncol; 1998 Jun; 69(3):205-9. PubMed ID: 9648588
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus infection and cervical cancer in Brazil: a retrospective study.
Cavalcanti SM; Deus FC; Zardo LG; Frugulhetti IC; Oliveira LH
Mem Inst Oswaldo Cruz; 1996; 91(4):433-40. PubMed ID: 9070405
[TBL] [Abstract][Full Text] [Related]
31. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas.
Koyamatsu Y; Yokoyama M; Nakao Y; Fukuda K; Saito T; Matsukuma K; Iwasaka T
Gynecol Oncol; 2003 Sep; 90(3):547-51. PubMed ID: 13678722
[TBL] [Abstract][Full Text] [Related]
32. Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA.
Thomas DB; Ray RM; Koetsawang A; Kiviat N; Kuypers J; Qin Q; Ashley RL; Koetsawang S
Am J Epidemiol; 2001 Apr; 153(8):723-31. PubMed ID: 11296143
[TBL] [Abstract][Full Text] [Related]
33. Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions.
Mourón SA; Abba MC; Güerci A; Gómez MA; Dulout FN; Golijow CD
Mutat Res; 2000 Aug; 469(1):127-34. PubMed ID: 10946249
[TBL] [Abstract][Full Text] [Related]
34. Vaccination to prevent and treat cervical cancer.
Roden RB; Ling M; Wu TC
Hum Pathol; 2004 Aug; 35(8):971-82. PubMed ID: 15297964
[TBL] [Abstract][Full Text] [Related]
35. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
36. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
[TBL] [Abstract][Full Text] [Related]
37. HPV induced cervical carcinogenesis: molecular basis and vaccine development.
Kaufmann AM; Backsch C; Schneider A; Dürst M
Zentralbl Gynakol; 2002 Nov; 124(11):511-24. PubMed ID: 12796844
[TBL] [Abstract][Full Text] [Related]
38. [Investigation of E6/E7 mRNAs of high risk human papilloma virus types by a commercial automatized NASBA assay in cervical swabs].
Ardiç N; Oztürk O; Ergünay K; Sezer O
Mikrobiyol Bul; 2009 Jul; 43(3):463-9. PubMed ID: 19795622
[TBL] [Abstract][Full Text] [Related]
39. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.
Mullokandov MR; Kholodilov NG; Atkin NB; Burk RD; Johnson AB; Klinger HP
Cancer Res; 1996 Jan; 56(1):197-205. PubMed ID: 8548763
[TBL] [Abstract][Full Text] [Related]
40. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
